Sanford Heisler Sharp Files $200 Million+ Class and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
80
Sanford Heisler Sharp Files $200 Million+ Class and Collective Action Against Jones Day

WASHINGTON, April 03, 2019 (GLOBE NEWSWIRE) -- Attorneys from Sanford Heisler Sharp, LLP today filed a $200,000,000+ gender, pregnancy, and maternity discrimination class and collective action in U.S. District Court for the District of Columbia against Jones Day.

The six plaintiffs – Nilab Rahyar Tolton, Andrea Mazingo, and Jane Does 1 through 4 – allege Jones Day is a fraternity led by one man. The Complaint details how Jones Day’s culture harms female associates in compensation and partnership decisions. The women are represented in the matter by David W. Sanford, Chairman of Sanford Heisler Sharp; Deborah K. Marcuse, Baltimore Managing Partner; and Russell L. Kornblith, New York Managing Partner.

“The Complaint chronicles how male senior partners give the best work to male associates, who earn more and are promoted more rapidly, and how female lawyers’ work is regularly undervalued,” said Marcuse.

The Complaint alleges that women who become pregnant and have children are assumed to be uncommitted to their work. For Plaintiff Tolton, all it took was asking a question about Firm policies relating to maternity leave to transform her reputation from that of a Harvard Law superstar to a problem child. When, the next year, she became pregnant herself and went out on leave, she returned to a salary freeze, unsubstantiated negative reviews, and diminished work opportunities. When she returned from a second leave, she was promptly told to look for a new job.

Plaintiff Mazingo worked tirelessly for Jones Day at great personal cost, but, as the Complaint recounts, she was denied mentorship opportunities, sexually harassed, and subjected to verbal abuse by a male partner when she was forced to take a weekend off for health reasons. Frozen out by that partner, the principal partner with whom she had worked, and deprived of any mentoring support to advance to partnership herself, Ms. Mazingo was forced to leave the Firm.

The Complaint also includes detailed allegations of gender discrimination and retaliation from four other former Jones Day associates who are seeking to proceed under pseudonyms.

Kornblith noted, “Jones Day proudly touts that it is not like its peer firms, because it does not pay its associates in lockstep. However, plaintiffs allege that this ‘black box’ compensation system masks gender discrimination in pay. It is time for Jones Day to open the black box and implement full pay transparency.”

The Complaint includes class allegations under Rule 23 of the Federal Rules of Civil Procedure, with the Rule 23 class comprising all female associates who are, have been or will be employed by Jones Day in the U.S. during the applicable liability period until the date of judgment. Plaintiffs bring class claims of gender discrimination on behalf of a nationwide class under both Title VII of the Civil Rights Act of 1964 and the District of Columbia Human Rights Act, the latter of which applies to allegedly discriminatory decisions made by Jones Day’s all-powerful Managing Partner, Stephen J. Brogan.

Plaintiffs also bring collective action claims under the federal Equal Pay Act and class claims on behalf of female Jones Day associates in California under, inter alia, the California Fair Employment and Housing Act; the California Family Rights Act; the California Equal Pay Act, as amended by the California Fair Pay Act; the California Business and Professions Code; and the California Private Attorneys General Act of 2004.

Since 2016, Sanford Heisler Sharp has represented female attorneys at more than twenty U.S. law firms who experienced career-crushing gender discrimination, shining a bright light on the dark employment practices that have historically prevented women from attaining compensation and leadership roles comparable to men throughout the legal profession.

For more information, contact Jamie Moss, newsPRos, 201-788-0142, jamie@newspros.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 387

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 544

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 109

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 305

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 411

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 174

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Breakthroughs in Lung Cancer Treatment with Reqorsa

Updated Category News Views 182

Innovative Advances in Lung Cancer Treatment The fight against lung cancer continues to evolve, showcasing promising advancements that bring new hope to patients. Genprex, Inc. is at the forefront of this battle with its revolutionary gene therapy known as Reqorsa. This cutting-edge treatment has been developed specifically to target KRAS mutation in non-small cell lung...

Continue Reading
EfTEN United Property Fund Reports October Earnings and NAV

Updated Category News Views 192

Insights into EfTEN United Property Fund's Recent Performance EfTEN United Property Fund demonstrated a net profit of 110 thousand euros for October, totaling 2.214 million euros for the first ten months of the year, marking a significant improvement from 724 thousand euros during the same period last year. This impressive financial outcome led to a distribution to...

Continue Reading
Cardiff Oncology Reports Encouraging Results in mCRC Trial

Updated Category News Views 236

Cardiff Oncology Reveals Promising Clinical Trial Results Cardiff Oncology, Inc. (Nasdaq: CRDF), a pioneering clinical-stage biotechnology company, has recently announced encouraging results from its ongoing CRDF-004 clinical trial. This randomized Phase 2 trial is investigating the effects of onvansertib in patients suffering from first-line RAS-mutated metastatic...

Continue Reading
Japan's Growing Casting Polyurethane Market and Its Future

Updated Category News Views 127

Japan's Casting Polyurethane Market: A Rising Force The Japan casting polyurethane market is on the verge of significant transformation, anticipated to elevate from a valuation of US$ 134.74 million to a remarkable US$ 248.24 million by 2033. This growth trajectory highlights a compelling compound annual growth rate (CAGR) of 7.08%, revealing the underlying strength...

Continue Reading
Hudson Technologies Faces Challenges Amid Downgrade by B.Riley

Updated Category News Views 353

B.Riley Downgrades Hudson Technologies Stock In a recent market statement, B.Riley has lowered its outlook on Hudson Technologies (NASDAQ: HDSN), shifting the stock rating from Buy to Neutral. This adjustment comes amidst new growth projections adjusted downwards from +16.6% to +8.5%. The modification in expectations has been linked to ongoing pressures on...

Continue Reading